Salvatore La Rosa

发表

Organ deformation and dose coverage in robotic respiratory-tracking radiotherapy.

Xing-Qi Lu, Anand Mahadevan, I. Kaplan, 2008, International journal of radiation oncology, biology, physics.

Frameless angiogram-based stereotactic radiosurgery for treatment of arteriovenous malformations.

E. Kasper, M. Stevenson, E. Holupka, 2012, International journal of radiation oncology, biology, physics.

SAR and biological evaluation of SEN12333/WAY-317538: Novel alpha 7 nicotinic acetylcholine receptor agonist.

T. Comery, Salvatore La Rosa, M. Pollastrini, 2009, Bioorganic & medicinal chemistry.

Creating a data resource: what will it take to build a medical information commons?

John Wilbanks, Robert Gentleman, Isaac S. Kohane, 2017, Genome Medicine.

A prototype solid phase synthesis of pteridines and related heterocyclic compounds.

Salvatore La Rosa, C. Gibson, C. Suckling, 2003, Organic & biomolecular chemistry.

Cutaneous neurofibromas in the genomics era: current understanding and open questions

Robert J. Allaway, J. Guinney, Salvatore La Rosa, 2018, British Journal of Cancer.

A high-throughput molecular data resource for cutaneous neurofibromas

S. Levy, H. Weinberg, J. Guinney, 2017, Scientific Data.

Cutaneous neurofibromas in the genomics era: current understanding and open questions

Robert J. Allaway, J. Guinney, Salvatore La Rosa, 2018, British Journal of Cancer.

EPH receptor signaling as a novel therapeutic target in NF2-deficient meningioma

Robert J. Allaway, Steven P. Angus, S. Haggarty, 2018, Neuro-oncology.

Traditional and systems biology based drug discovery for the rare tumor syndrome neurofibromatosis type 2

Robert J. Allaway, Steven P. Angus, S. Haggarty, 2018, PloS one.

Funding community collaboration to develop effective therapies for neurofibromatosis type 1 tumors

Salvatore La Rosa, J. Blakeley, S. Verma, 2019, EMBO molecular medicine.

Brigatinib causes tumor shrinkage in both NF2-deficient meningioma and schwannoma through inhibition of multiple tyrosine kinases but not ALK

Steven P. Angus, David C. Jones, M. Ferrer, 2021, PloS one.

Novel Hits in the Correction of ΔF508-Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Protein: Synthesis, Pharmacological, and ADME Evaluation of Tetrahydropyrido[4,3-d]pyrimidines for the Potential Treatment of Cystic Fibrosis.

Letizia Magnoni, Laura Maccari, Nicoletta Pedemonte, 2015, Journal of medicinal chemistry.

Creating a data resource: what will it take to build a medical information commons?

R. Gibbs, E. Boerwinkle, R. Gentleman, 2017, Genome Medicine.

Engaging a community to enable disease-centric data sharing with the NF Data Portal

Robert J. Allaway, Salvatore La Rosa, Sharad Verma, 2019, Scientific Data.

Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).

T. Comery, K. Marquis, S. Grauer, 2010, Journal of medicinal chemistry.

Fused 3-Hydroxy-3-trifluoromethylpyrazoles Inhibit Mutant Huntingtin Toxicity.

O. Gokce, Salvatore La Rosa, Giulia Lazzeroni, 2013, ACS medicinal chemistry letters.

A Phenotypic Screening Assay for Modulators of Huntingtin-Induced Transcriptional Dysregulation

A. Caricasole, Salvatore La Rosa, Giulia Lazzeroni, 2013, Journal of biomolecular screening.

Novel alpha-7 nicotinic acetylcholine receptor agonists containing a urea moiety: identification and characterization of the potent, selective, and orally efficacious agonist 1-[6-(4-fluorophenyl)pyridin-3-yl]-3-(4-piperidin-1-ylbutyl) urea (SEN34625/WYE-103914).

T. Comery, K. Marquis, S. Grauer, 2010, Journal of medicinal chemistry.